TriangleDecitabine-cedazuridine plus… (NCT07710534)
Decitabine-cedazuridine plus venetoclax (DEC-C+VEN) trial for Relapsed / Refractory AML (NCT07710534). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk accelerated-phase myeloproliferative neoplasms. Previous combined hypomethylating-agent and venetoclax treatment excludes participation.
The idea: compare weekly oral decitabine-cedazuridine plus venetoclax with azacitidine plus venetoclax. Decitabine alters DNA methylation; cedazuridine slows its breakdown. Venetoclax blocks BCL-2, a protein that helps cancer cells survive. Random assignment selects treatment. Researchers compare serious treatment-related side effects. Treatment can stop for progression, toxicity or allogeneic transplant.
This phase 2 study plans 40 patients. Keri Maher leads Virginia Commonwealth University's recruiting Richmond site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.